Dr. Christopher D. Nevala-Plagemann
Claim this profileHuntsman Cancer Institute/University of Utah
Studies Gastroesophageal Junction Adenocarcinoma
Studies Rectal Cancer
6 reported clinical trials
11 drugs studied
Area of expertise
1Gastroesophageal Junction Adenocarcinoma
Stage IV
Stage III
HER2 negative
2Rectal Cancer
Stage IV
Stage III
pMMR positive
Affiliated Hospitals
Clinical Trials Christopher D. Nevala-Plagemann is currently running
Nivolumab + Standard Treatment
for Stomach and Esophageal Cancer
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting1 award Phase 2 & 320 criteria
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
More about Christopher D. Nevala-Plagemann
Clinical Trial Related1 year of experience running clinical trials · Led 6 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Christopher D. Nevala-Plagemann has experience with
- Nivolumab
- Gemcitabine
- Nab-paclitaxel
- VCN-01
- Topical Tretinoin
- Cetuximab
Breakdown of trials Christopher D. Nevala-Plagemann has run
Gastroesophageal Junction Adenocarcinoma
Rectal Cancer
Esophageal cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christopher D. Nevala-Plagemann specialize in?
Christopher D. Nevala-Plagemann focuses on Gastroesophageal Junction Adenocarcinoma and Rectal Cancer. In particular, much of their work with Gastroesophageal Junction Adenocarcinoma has involved Stage IV patients, or patients who are Stage III.
Is Christopher D. Nevala-Plagemann currently recruiting for clinical trials?
Yes, Christopher D. Nevala-Plagemann is currently recruiting for 4 clinical trials in Salt Lake City Utah. If you're interested in participating, you should apply.
Are there any treatments that Christopher D. Nevala-Plagemann has studied deeply?
Yes, Christopher D. Nevala-Plagemann has studied treatments such as Nivolumab, Gemcitabine, Nab-paclitaxel.
What is the best way to schedule an appointment with Christopher D. Nevala-Plagemann?
Apply for one of the trials that Christopher D. Nevala-Plagemann is conducting.
What is the office address of Christopher D. Nevala-Plagemann?
The office of Christopher D. Nevala-Plagemann is located at: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah 84112 United States. This is the address for their practice at the Huntsman Cancer Institute/University of Utah.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.